Floatz logo

BAY-63-2521

Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

BayerPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary cohort.

Asset / SponsorPhaseRating
Riociguat
Bayer
Phase 2CCC

Same molecule, other indications

BAY-63-2521 is also rated in:

cystic fibrosisDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →